On December 13, it was reported that the Beijing Municipal Health Commission has responded to multiple medical checkup complaints filed by Ms. Zhang Xiaoling, issuing a formal reply (No. 11017, 2025). The document states that after multiple rounds of investigation, no major violations—such as misdiagnosis, missed diagnoses, or data falsification—were found in the core checkup services provided by institutions including Peking University Medical Rehabilitation Hospital and iKang Guobin-affiliated clinics. However, some facilities were penalized for issues like improper medical waste management and incomplete staff registration records.
The dispute, which lasted six months, began in July 2025 when Ms. Zhang filed complaints through integrated platforms and central inspection teams. She alleged that iKang Guobin-affiliated clinics and related hospitals had missed critical diagnoses, falsified checkup data, and conducted non-compliant tumor marker tests (including CEA), leading to delayed treatment and permanent disability. Her demands included revoking the institutions’ checkup qualifications, suspending doctors’ licenses, and pursuing criminal liability. The Beijing Health Commission stated in its reply that it launched an investigation in September after collecting additional evidence and holding face-to-face discussions with the complainant.
Regarding the claim of "misdiagnosis and missed diagnoses at Peking University Medical Rehabilitation Hospital," the reply clarified that Ms. Zhang had undergone a cardiovascular checkup package, which did not include imaging for joints or the spine. Physical examinations showed no abnormalities, while the ultrasound report noted right kidney irregularities and recommended further hospital follow-up—a reasonable suggestion. The commission found "no evidence of misdiagnosis or missed diagnoses warranting suspension or revocation of the hospital’s checkup qualifications."
Concerning CEA testing services at iKang Guobin and Peking University Medical Rehabilitation Hospital, the commission confirmed that CEA tests are a standard clinical diagnostic tool and may be conducted by medical institutions in compliance with regulations. "No grounds were found to halt such testing." Blood samples from iKang Guobin’s Xinei and Xisanqi clinics were sent to its Zhongguancun Central Laboratory in Beijing, which holds quality certification. The lab’s personnel, equipment, and reagents met regulatory standards, and test results were traceable. Peking University Medical Rehabilitation Hospital’s lab also passed national quality assessments, ensuring reliable results. No data falsification was uncovered.
On disciplinary actions, the reply disclosed that Dr. Yang from Beijing Jishuitan Hospital was reprimanded and suspended for improper patient referrals, with the department and its director also penalized. However, no license revocations or hospital downgrades were deemed necessary. iKang Guobin’s Xisanqi clinic faced corrective orders and demerits for unregistered multi-practice physicians, incomplete checkup reports, and improper medical waste records, while its Xinei clinic received a warning and a 2,000-yuan fine for substandard waste storage.
The commission also reviewed complaints about the doctors’ academic credentials and publications, finding no evidence of fraud in their promotions, degrees, or research papers. For unresolved disputes, the commission agreed with Ms. Zhang to initiate a medical malpractice appraisal, with further actions to follow based on the findings.
The reply emphasized that Ms. Zhang may apply for administrative reconsideration within 60 days or file a lawsuit at Tongzhou District People’s Court within six months if she disputes the outcome.